Bahamas vs Cyprus: HIV/AIDS deaths averted by antiretroviral therapy
Bahamas
60.36 deaths
in 2024
Cyprus
64 deaths
in 2021
Bahamas rank
133rd
Cyprus rank
131st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bahamas
- Cyprus
How they compare
Cyprus currently reports 64 deaths against 60.36 deaths in Bahamas, a difference of 3.64 deaths.
That makes Cyprus's figure about 1.1 times Bahamas's.
The two have swapped places 1 time across 32 shared years of data; in 1990 it was Cyprus ahead.
Bahamas ranks 133rd and Cyprus ranks 131st of 157 countries.
Bahamas has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bahamas | Cyprus | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 113.16 deaths | 11.5 deaths | 101.66 deaths | Bahamas |
| 2010s | 136.56 deaths | 42.1 deaths | 94.46 deaths | Bahamas |
| 2020s | 111.79 deaths | 63.5 deaths | 48.29 deaths | Bahamas |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bahamas or Cyprus?
- Cyprus, at 64 deaths against 60.36 deaths in Bahamas as of 2021.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bahamas and Cyprus?
- 3.64 deaths, with Cyprus ahead.
- How many years of comparable data are there for Bahamas and Cyprus?
- 32 years are reported by both, from 1990 to 2021.
- How do Bahamas and Cyprus rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bahamas ranks 133rd and Cyprus ranks 131st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.